Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-73763924
- Development stage
- Unknown
- Lead developer
- Janssen Research & Development
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
JNJ-73763924 is a chemically synthesized, N-acetylgalactosamine–conjugated short-interfering RNA (siRNA) designed as a targeted therapy for chronic hepatitis B virus (HBV) infection. It is a component of the combination therapy JNJ-73763989, which comprises two liver-targeted siRNA triggers (JNJ-73763976 and JNJ-73763924) that silence viral transcripts through RNA interference. The N-acetylgalactosamine conjugation enables selective hepatocyte delivery via the asialoglycoprotein receptor, providing liver specificity. JNJ-73763924 displays a relatively short plasma half-life, absorption rate-limited kinetics, and high affinity for hepatic uptake, with the combination approach designed to maximize reduction of HBV surface antigen. It is being developed by Johnson & Johnson for subcutaneous administration in patients with chronic hepatitis B.
- Other names
- JNJ 73763924JNJ73763924JNJ-73763924
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)
Beyond the preview
Go deeper on JNJ-73763924.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-73763924.